<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012670</url>
  </required_header>
  <id_info>
    <org_study_id>KZA-0084-102</org_study_id>
    <secondary_id>QSC204878</secondary_id>
    <nct_id>NCT05012670</nct_id>
  </id_info>
  <brief_title>Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects</brief_title>
  <official_title>An Open-Label, Single-Dose, Single-Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kazia Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kazia Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre, open-label, non-randomised study to assess the mass balance recovery, PK,&#xD;
      metabolite profile, and metabolite identification of a single oral dose of 14C labelled&#xD;
      paxalisib ([14C] Paxalisib) in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the mass balance recovery after a single oral dose of carbon-14 ([14C])-Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Mass balance recovery of total radioactivity (TR) in all excreta (urine and faeces): CumAe (amount excreted) and Cum%Ae</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To provide plasma samples for metabolite profiling and structural identification</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Collection of plasma samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To provide urine samples for metabolite profiling and structural identification</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Collection of urine samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To provide faecal samples for metabolite profiling and structural identification</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Collection of faecal samples for metabolite profiling, structural identification, and quantification analysis of paxalisib metabolites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the routes and rates of elimination of [14C]-Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Calculation of Ae, %Ae, CumAe, and Cum%Ae for TR by interval in urine and faeces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify the chemical structure of each metabolite accounting for more than 10% (in plasma) of circulating TR or metabolites in excreta (urine and faeces) that account for more than 10% of the administered radioactive dose</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Identification of the chemical structure of each paxalisib metabolite accounting for more than 10% by area under the curve (AUC) of circulating TR in plasma to identify major metabolites, and identification of each metabolite in excreta (urine and faeces) that accounts for more than 10% of the administered radioactive dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the Cmax pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to Cmax parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the Tmax pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to Tmax parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) parameter of paxalisib following administration of [14C] Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of paxalisib in plasma including but not limited to AUC(0-last) and AUC(0-inf) parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the Cmax pharmacokinetic (PK) of TR following administration of [14C] Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of TR in plasma including but not limited to Cmax parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the Tmax pharmacokinetic (PK) of TR following administration of [14C] Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of TR in plasma including but not limited to Tmax parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the AUC(0-last) and AUC(0-inf) pharmacokinetic (PK) of TR following administration of [14C] Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Assessment of the PK of an oral [14C]-Paxalisib formulation by measurement of TR in plasma including but not limited to AUC(0-last) and AUC(0-inf) parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the extent of distribution of TR into blood cells</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Evaluation of whole blood:plasma concentration ratios for TR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide adverse event (AE) safety information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>To provide safety information for paxalisib by assessing adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide blood pressure vital sign safety information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Measuring and assessing blood pressure in standard clinical units and against reference range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide heart rate vital sign safety information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Measuring and assessing heart rate in standard clinical units against reference range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide oral temperature vital sign safety information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Measuring and assessing oral temperature in standard clinical units against reference range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide respiratory rate vital sign safety information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Measuring and assessing respiratory rate in standard clinical units against reference range .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide electrocardiogram (ECG) safety information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Determination of standard ECG parameters including but not limited to PR interval, QRS duration, in standard clinical units against reference range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide physical examination safety information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Assessment of standard clinical whole-body targeted (symptom-driven) physical examination including but not limited to e.g. general appearance, dermatological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide hematology laboratory safety testing information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Measuring and assessing standard array of hematology parameters (e.g. white blood cell count) in standard clinical unit against reference range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide clinical chemistry laboratory safety testing information for paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Measuring and assessing standard array of clinical chemistry parameters (e.g. cholesterol) in standard clinical unit against reference range</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the urine PK of paxalisib following administration of [14C] Paxalisib</measure>
    <time_frame>Day 1 to Day 8 (or up to Day 10 if discharge criteria not met at Day 8)</time_frame>
    <description>Determination of [14C] Paxalisib and calculation of Ae (amount excreted), CumAe (cummulative amount excreted), %Ae (fraction of dose excreted) and Cum%Ae (cummulative fraction of dose excreted) as appropriate for paxalisib in urine</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C]-Paxalisib Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be dosed on the morning of Day 1 following an overnight fast of a minimum of 10 h. Subjects will remain resident in the clinical unit until 168 h post dose (Day 8) and this may be extended up to a maximum of 48 h (i.e., up to Day 10).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-Paxalisib Capsule</intervention_name>
    <description>Each subject will receive a single dose 15 mg (NMT 3.5 MBq), administered orally in the fasted state with with 240 mL water.</description>
    <arm_group_label>[14C]-Paxalisib Capsule</arm_group_label>
    <other_name>Phosphoinositide 3-kinase (PI3K) Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males.&#xD;
&#xD;
          2. Aged 30 to 65 years inclusive at the time of signing informed consent.&#xD;
&#xD;
          3. Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.&#xD;
&#xD;
          4. Must be willing and able to communicate and participate in the whole study.&#xD;
&#xD;
          5. Must have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools&#xD;
             per day).&#xD;
&#xD;
          6. Must provide written informed consent.&#xD;
&#xD;
          7. Must agree to adhere to the contraception requirements defined in study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received any IMP in a clinical research study within the 90 days&#xD;
             prior to Day 1.&#xD;
&#xD;
          2. Subjects who are, or are immediate family members of, a study site or sponsor&#xD;
             employee.&#xD;
&#xD;
          3. Evidence of current SARS-CoV-2 infection.&#xD;
&#xD;
          4. History of any drug or alcohol abuse in the past 2 years.&#xD;
&#xD;
          5. Regular alcohol consumption &gt;21 units per week (1 unit = ½ pint beer, or a 25 mL shot&#xD;
             of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).&#xD;
&#xD;
          6. A confirmed positive alcohol breath test at screening or admission.&#xD;
&#xD;
          7. Current smokers and those who have smoked within the last 12 months. A confirmed&#xD;
             breath carbon monoxide reading of greater than 10 ppm at screening or admission.&#xD;
&#xD;
          8. Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months.&#xD;
&#xD;
          9. Subjects with pregnant or lactating partners.&#xD;
&#xD;
         10. Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,&#xD;
             as defined in the Ionising Radiation Regulations 2017, shall participate in the study.&#xD;
&#xD;
         11. Subjects who have been administered IMP in an ADME study in the last 12 months.&#xD;
&#xD;
         12. Subjects who do not have suitable veins for multiple venepunctures/cannulation as&#xD;
             assessed by the investigator or delegate at screening.&#xD;
&#xD;
         13. Clinically significant abnormal clinical chemistry, haematology, or urinalysis as&#xD;
             judged by the investigator (laboratory parameters are listed in study protocol).&#xD;
&#xD;
         14. Confirmed positive drugs of abuse test result (drugs of abuse tests are listed in&#xD;
             study protocol)&#xD;
&#xD;
         15. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or&#xD;
             human immunodeficiency virus (HIV) antibody results&#xD;
&#xD;
         16. Evidence of renal impairment at screening, as indicated by an estimated creatinine&#xD;
             clearance (CLcr) of &lt;80 mL/min using the Cockcroft-Gault equation.&#xD;
&#xD;
         17. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory&#xD;
             disease, neurological, or psychiatric disorder, as judged by the investigator.&#xD;
&#xD;
         18. History of clinically significant GI disease, especially peptic ulceration, GI&#xD;
             bleeding, ulcerative colitis, Crohn's Disease, or Irritable Bowel Syndrome.&#xD;
&#xD;
         19. Any history of pre-diabetes, diabetes mellitus (any type), or hyperglycaemia. At&#xD;
             screening, fasting blood glucose and HbA1c must be within the normal range.&#xD;
&#xD;
         20. History or presence of significant dermatological disorders or skin rashes, as judged&#xD;
             by the investigator.&#xD;
&#xD;
         21. Subject had a QTcF of &gt;450 msec based on ECG at screening or at pre dose, or a history&#xD;
             of additional risk factors for Torsades de Pointe (e.g., hypokalaemia, hypomagnesia, a&#xD;
             family history of long QT syndrome).&#xD;
&#xD;
         22. Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients.&#xD;
&#xD;
         23. Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hay fever is allowed unless it is active.&#xD;
&#xD;
         24. Donation of blood or plasma within the previous 3 months or loss of greater than 400&#xD;
             mL of blood.&#xD;
&#xD;
         25. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or&#xD;
             herbal remedies (other than up to 4 g of paracetamol per day) within 14 days before&#xD;
             IMP administration (see Section 11.4). COVID-19 vaccines are accepted concomitant&#xD;
             medications, except for within 72 h of dosing. Exceptions may apply on a case by case&#xD;
             basis, if considered not to interfere with the objectives of the study, as determined&#xD;
             by the investigator.&#xD;
&#xD;
         26. Subjects who have had a COVID-19 vaccine within 72 h (3 days) before IMP&#xD;
             administration.&#xD;
&#xD;
         27. History of GI surgery (with the exception of appendectomy unless it was performed&#xD;
             within the previous 12 months).&#xD;
&#xD;
         28. Acute diarrhoea or constipation in the 7 days before the predicted Day 1. If screening&#xD;
             occurs &gt;7 days before the Day 1, this criterion will be determined on Day 1. Diarrhoea&#xD;
             will be defined as the passage of liquid faeces and/or a stool frequency of greater&#xD;
             than 3 times per day. Constipation will be defined as a failure to open the bowels&#xD;
             more frequently than every other day.&#xD;
&#xD;
         29. Failure to satisfy the investigator of fitness to participate for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Evans, MBChB, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

